Status:

UNKNOWN

Mesenchymal Stem Cell for Osteonecrosis of the Femoral Head

Lead Sponsor:

Jianming Tan

Conditions:

Osteochondritis of the Femoral Head

Eligibility:

All Genders

12-60 years

Phase:

EARLY_PHASE1

Brief Summary

Mesenchymal Stem Cells (MSCs) have been shown to have immunosuppressive and repairing properties. Bone marrow mononuclear cells (BMMNCs) have revascularization properties and complimentary effects to ...

Detailed Description

Mesenchymal Stem Cells (MSCs) have been shown to have immunosuppressive and repairing properties. Bone marrow mononuclear cells (BMMNCs) have revascularization properties and complimentary effects to ...

Eligibility Criteria

Inclusion

  • Ages: 12 to 60 years old.
  • Association Research Circulation Osseous(ARCO) Classification criteria for osteonecrosis of the femoral head: ARCO phase I and phase II.
  • Able to give informed consent.

Exclusion

  • Pregnant women.
  • Previous history of malignancy
  • Active infection including hepatitis B, hepatitis C, HIV, or TB as determined by a positive skin test or clinical presentation, or under treatment for suspected TB.
  • Evidence of cardiovascular disease, existing congestive cardiac failure on physical exam and/or acute coronary syndrome in the past 6 months.
  • Psychiatric illness or mental deficiency making compliance with treatment or informed consent impossible.
  • Any illness that in the opinion of the investigator would jeopardize the ability of the Patient to tolerate this treatment.

Key Trial Info

Start Date :

December 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2015

Estimated Enrollment :

15 Patients enrolled

Trial Details

Trial ID

NCT00813267

Start Date

December 1 2009

End Date

August 1 2015

Last Update

October 10 2012

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Fuzhou General Hospital

Fuzhou, Fujian, China, 350025